A calculator to help people understand their risk factors for COVID-19 infection and vaccination has been launched by the Immunisation Coalition in collaboration with Australian researchers.
Cherwell Laboratories, manufacturer of Redipor® prepared culture media, announces that it has added ANT Medikal, in Turkey, to its international distribution network for the Redipor range, as part of the company’s continued strategic focus on building its overseas markets.
A new study published on the bioRxiv* preprint server investigates changes in household food insecurity throughout the first year of the COVID-19 pandemic. To do this, researchers followed a cohort of Vermonters and examined the socio-demographic characteristics correlated with increased odds of experiencing food insecurity.
The brain is the most complex organ in the human body. Now, a new study has brought us closer to understanding some of its evolution. It shows that human brains decreased in size approximately 3,000 years ago.
Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, today announced the launch of the CFX™ Opus 96 Dx System and the CFX™ Opus 384 Dx System, real-time PCR detection systems that have been listed with the U.S. Food and Drug Administration for IVD testing and that meet the CE-IVD requirement for IVD use in Europe.
New research published in the medRxiv* preprint server suggests that COVID-19 illness incurs a greater 90-day risk of venous thrombosis than the flu. However, arterial thrombosis remains a higher risk among people with the influenza virus.
The coronavirus disease 2019 (COVID-19) pandemic brought in its wake a slew of restrictions on leaving the house, social interactions and educational or business opportunities. For very young children growing up under these conditions, the change is marked. A new study from the UK reports the effect of these changes in the typical pattern of life on preschool children.
Researchers report the binding and pseudo-neutralizing antibody titers elicited after patients had received either the Pfizer-BioNTech or AstraZeneca vaccines.
Researchers discuss mutations in the NTD of the spike protein, which contains an antigenic “supersite” and is the target for nAbs.
Researchers compare antibody titers elicited the Pfizer‐BioNTech mRNA and the classic inactivated virus Sinopharm vaccines.